Jasper Therapeutics CFO Herb Cross to resign, interim officers named

Jasper Therapeutics disclosed in an 8-K dated September 28, 2026 that on September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of the company in order to pursue other professional endeavors.¹

To fill the gap, on September 28, 2026, the board of directors appointed Jeet Mahal, the company's President and Chief Executive Officer, as interim Principal Financial Officer, Rick Ruiz, the company's Vice President, Finance, as interim Principal Accounting Officer, and Matthew Ros, the company's Chief Operating Officer, as interim Corporate Secretary, each effective as of Mr. Cross's resignation.¹

The filing includes background on Ruiz, age 62, noting he joined the company in 2024 as Vice President, Finance and is a finance executive with over 25 years of experience encompassing accounting, financing, FP&A and SEC reporting.¹ Prior roles included Vice President, Finance at Atreca, and before that a consultant at RoseRyan, a finance and accounting consulting firm, as well as Corporate Controller at Audible Magic Corp, with his career beginning at KPMG and a bachelor's degree from Biola University.¹ He is a certified public accountant, currently inactive, in the state of California.¹

The company stated there are no family relationships between Ruiz and any of the company's directors or other executive officers, and no arrangements or understandings tied to his appointment as interim Principal Accounting Officer.¹ On compensation, Ruiz will continue to receive a base salary of $364,000 per year and remains eligible for equity awards under the company's equity plan, though he did not receive any equity awards in connection with his promotion.¹

The 8-K, dated September 28, 2026, was signed by Cross in his outgoing capacity as Chief Financial Officer.